metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)
versus sunitinib
	atezolizumab alone vs. sunitinib	1	-	1.19 [0.82; 1.72], 1 RCT, I2=0% inconclusive result	-
	atezolizumab plus bevacizumab vs. sunitinib	2	0.93 [0.76; 1.14], 1 RCT, I2=0% inconclusive result	0.90 [0.77; 1.05], 2 RCTs, I2=0% inconclusive result	-
mRCC - L1 - PDL1 negative metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 negative
versus sunitinib
	atezolizumab plus bevacizumab vs. sunitinib	1	-	0.84 [0.67; 1.05], 1 RCT, I2=0% inconclusive result	-
mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive
versus sunitinib
	atezolizumab alone vs. sunitinib	1	-	1.03 [0.63; 1.68], 1 RCT, I2=0% inconclusive result	-
	atezolizumab plus bevacizumab vs. sunitinib	2	0.84 [0.62; 1.14], 1 RCT, I2=0% inconclusive result	0.83 [0.59; 1.16], 2 RCTs, I2=37% inconclusive result	-
metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)